8N10 Stock Chart & Stats
€0.56
€0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range€0.46 - €9.23
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€1.43M
Enterprise Value€77.44
Total Cash (Recent Filing)€15.37M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.38
Shares Outstanding2,348,232
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)7.89
Price to Sales (P/S)0.00
P/FCF Ratio-2.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.93
Revenue Forecast (FY)€129.54K
Bulls Say, Bears Say
Bulls Say
Focused Antifungal Pipeline (BSG005)Biosergen’s R&D is concentrated on BSG005, a modified amphotericin B targeting invasive fungal infections. A single, specialized core asset focuses resources on an unmet clinical area, enabling clear development milestones, partnership potential and licensing value if clinical data are positive.
Debt-free Balance SheetThe absence of reported debt lowers solvency and interest-rate risk, giving management structural flexibility to prioritize R&D and negotiate financing on more favorable terms. For a small biotech, a debt-free position materially reduces near-term default pressure and preserves optionality.
Ability To Moderate Cash BurnThe company has demonstrated the ability to materially adjust cash burn year-to-year (notably 2024 improved vs 2023), indicating operational flexibility to preserve runway. This capacity to scale spending helps manage financing cadence and extend development windows when needed.
Bears Say
Pre-revenue ProfileBiosergen is fully pre-commercial with no revenue since 2022, leaving the business dependent on external capital or partnerships. Without product sales, the company cannot internally fund trials long-term, increasing dilution risk and making execution sensitive to financing availability.
Widening Losses And Rising Cash Burn (2025)Losses and cash burn increased sharply in 2025 (net loss ~SEK 40.8M; free cash flow ~-SEK 36.8M), materially raising near-term financing needs. Escalating spend without revenue heightens the likelihood of dilutive capital raises or program delays, stressing long-term development plans.
Shrinking Equity And Total AssetsEquity and total assets declined materially in 2025 (equity ~SEK 48.2M to ~SEK 11.8M; assets ~SEK 52.9M to ~SEK 19.8M), eroding the company’s resource cushion. A depleted balance sheet reduces shock absorption and bargaining power in financings or partnerships, increasing structural vulnerability.
8N10 FAQ
What was Biosergen AB’s price range in the past 12 months?
Biosergen AB lowest stock price was €0.46 and its highest was €9.22 in the past 12 months.
What is Biosergen AB’s market cap?
Biosergen AB’s market cap is €1.43M.
When is Biosergen AB’s upcoming earnings report date?
Biosergen AB’s upcoming earnings report date is Aug 19, 2026 which is in 23 days.
How were Biosergen AB’s earnings last quarter?
Currently, no data Available
Is Biosergen AB overvalued?
According to Wall Street analysts Biosergen AB’s price is currently Undervalued.
Does Biosergen AB pay dividends?
Biosergen AB does not currently pay dividends.
What is Biosergen AB’s EPS estimate?
Biosergen AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biosergen AB have?
Biosergen AB has 2,348,232 shares outstanding.
What happened to Biosergen AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biosergen AB?
Currently, no hedge funds are holding shares in DE:8N10
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biosergen AB
Biosergen AB is a biopharmaceutical company specializing in the creation of antifungal medications. Its key development initiative is BSG005, an experimental antifungal drug candidate engineered to treat critical invasive fungal infections. The firm was established in 2004 and operates from its headquarters located in Solna, Sweden.